Laura Lin

USPTO Granted Patents = 10 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 100(Granted Patents)

Company Filing History:

4. 1 out of 832,843

Other

patents

Years Active: 2004-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11597770 - Anti-E-selectin antibodies, compositions and methods of use (2023-03-07),

2. 11155610 - Dual PDGF/VEGF antagonists (2021-10-26),

3. 11059876 - IL-15 variants and uses thereof (2021-07-13),

4. 10570189 - Muteins of clotting factor VIII (2020-02-25),

5. 9840553 - Dual PDGF/VEGF antagonists (2017-12-12),

6. 8221752 - Antibodies against human interleukin-13 and uses therefor (2012-07-17),

7. 7615213 - Antibodies against human interleukin-13 and pharmaceutical compositions thereof (2009-11-10),

8. 7584087 - Structure of protein kinase C theta (2009-09-01),

9. 7135319 - Crystals of an acyl carrier protein synthase/acyl carrier protein complex (2006-11-14),

10. 6684162 - Methods for identifying agents that interact with an active site of acyl carrier protein synthase-acyl carrier protein complex (2004-01-27),

Title: The Innovative Journey of Laura Lin

Introduction

Laura Lin, an accomplished inventor residing in Weston, MA, has made significant contributions to the fields of biotechnology and pharmaceuticals through her innovative inventions. With a remarkable portfolio of 10 patents, she has established herself as a prominent figure in her industry.

Latest Patents

Among her latest patents, Laura has developed groundbreaking innovations such as anti-E-selectin antibodies, which provide specific binding to E-selectin. This invention not only includes the antibodies but also the methods of utilizing them in various applications. Another noteworthy patent is the development of dual PDGF/VEGF antagonists. This invention comprises a VEGF antagonist linked to a PDGF antagonist, aimed primarily at treating wet age-related macular degeneration. The dual antagonist is designed to include a half-life extending moiety, improving its efficacy and usability in therapeutic settings.

Career Highlights

Throughout her career, Laura Lin has made impactful strides while working with esteemed organizations, including Wyeth and Pfizer Corporation. Her innovative spirit and expertise have contributed to significant advancements in therapeutic solutions for various diseases.

Collaborations

Laura has collaborated with talented professionals like William Stuart Somers and Kevin Delos Parris. These partnerships have fostered an environment of creativity and innovation, propelling her inventions to new heights.

Conclusion

With her impressive list of patents and collaborations, Laura Lin continues to be a driving force in the realm of innovation. Her dedication to research and development shapes the future of biotechnology and pharmaceutical therapies, leaving a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.